Thermo Fisher to acquire viral vector CDMO Brammer Bio for $1.7bn
Global life sciences company Thermo Fisher Scientific has agreed to acquire Massachusetts-based Brammer Bio from Ampersand Capital Partners for about $1.7 billion in cash. Brammer Bio is a viral vector contract development and manufacturing organization (CDMO) serving bipharma companies seeking to develop and commercialize gene therapies. The CDMO was formed in 2016 through the merger […]